Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avapritinib in advanced systemic mastocytosis
NL-OMON55851Phase 2Recruiting
- Sponsor
- Blueprint Medicines
- Start
- Aug 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avapritinib in systemic mastocytosis (SM), Aggressive Systemic Mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN) and 1 more, sponsored by Blueprint Medicines. Primary endpoint: Adjudicated overall response rate. Started Aug 2019; status: recruiting.
02
Drugs
avapritinib
03
Conditions
systemic mastocytosis (SM)Aggressive Systemic Mastocytosis (ASM)systemic mastocytosis with associated hematological neoplasm (SM-AHN)mast cell leukemia (MCL)
Beyond the preview
Go deeper on NL-OMON55851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55851.